Papageno Video for Suicide Prevention

Overseen By Jane Harness

Age: 18 - 65

Sex: Any

Trial Phase: Academic

Sponsor: University of Michigan

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 4

600 Participants Needed

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the Papageno treatment for suicide prevention?

The PROSPECT study showed that a care management intervention can reduce suicidal thoughts and depression in older patients, suggesting that structured support and intervention can be effective in suicide prevention. ^{1 2 3 4 5}

How is the Papageno Video treatment unique for suicide prevention?

The Papageno Video treatment is unique because it uses media stories of hope and recovery to reduce suicidal thoughts, leveraging the Papageno effect, which is the protective influence of positive media stories on vulnerable individuals. This approach contrasts with traditional methods that may not focus on media influence and storytelling as a preventive measure. ^{6 7 8 9 10}

What is the purpose of this trial?

The purpose of this study is to determine the effects of a short "Papageno story" video of a compilation of interviews on proximal risk factors for suicide. The researchers believe that the intervention may increase protective factors related to suicide.

Research Team

Jane Harness, DO

Principal Investigator

University of Michigan

Cheryl King, PhD

Principal Investigator

University of Michigan

Eligibility Criteria

This trial is for individuals at risk of suicide who may benefit from viewing a video designed to increase protective factors against suicide. Specific eligibility criteria are not provided, but typically participants would need to meet certain mental health conditions.

Inclusion Criteria

In the past year, I have wished to be dead or not wake up.

People who are part of an existing cohort within DesignXM

Exclusion Criteria

No exclusions if all inclusion criteria is met

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Intervention

Participants watch a 'Papageno story' video or a control video to assess effects on proximal risk factors for suicide

1 day

1 visit (in-person or virtual)

Follow-up

Participants are monitored for changes in suicidal ideation, hopelessness, and perceived agency

3 months

Assessments immediately before and after video, and at 3 months

Treatment Details

Interventions

• Papageno

Trial Overview The study is testing the impact of a 'Papageno story' video, which includes interviews that could help prevent suicide by increasing protective factors. Participants will be compared with those watching a control video.

Participant Groups

Group I: Papageno video Experimental Treatment 1 Intervention

The arm will watch a compilation of interviews on proximal risk factors for suicide

Group II: Control video Active Control 1 Intervention

The arm will watch an educational control video

Who Is Running the Clinical Trial?

University of Michigan

Lead Sponsor

Trials

1,891

Recruited

6,458,000+

American Foundation for Suicide Prevention

Collaborator

Trials

36

Recruited

10,500+

Ouida Scholar Award

Collaborator

Trials

1

Recruited

600+

Findings from Research

The Signs of Suicide (SOS) prevention program significantly reduced self-reported suicide attempts among high school students, as shown in a study involving 2,100 students across 5 schools.

Students in the intervention group also exhibited greater knowledge and more positive attitudes towards depression and suicide, indicating that the program not only helps reduce attempts but also improves understanding of these issues.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

An outcome evaluation of the SOS Suicide Prevention Program. Aseltine, RH., DeMartino, R.[2022]

References

1. Brazil pubmed.ncbi.nlm.nih.gov

Brazilian Psychiatric Association guidelines for the management of suicidal behavior. Part 1. Risk factors, protective factors, and assessment. [2022]

2. United States pubmed.ncbi.nlm.nih.gov

An outcome evaluation of the SOS Suicide Prevention Program. [2022]

3. England pubmed.ncbi.nlm.nih.gov

Practical suicide-risk management for the busy primary care physician. [2022]

4. England pubmed.ncbi.nlm.nih.gov

Cultural adaptation of the mental health first aid guidelines for assisting a person at risk of suicide in Brazil: a Delphi expert consensus study. [2022]

5. United States pubmed.ncbi.nlm.nih.gov

Reducing suicidal ideation and depression in older primary care patients: 24-month outcomes of the PROSPECT study. [2022]

6. England pubmed.ncbi.nlm.nih.gov

Effects of suicide awareness materials on individuals with recent suicidal ideation or attempt: online randomised controlled trial. [2021]

7. England pubmed.ncbi.nlm.nih.gov

Feasibility of a web-based suicide awareness programme for Asian American college students. [2022]

8. England pubmed.ncbi.nlm.nih.gov

Effects of media stories of hope and recovery on suicidal ideation and help-seeking attitudes and intentions: systematic review and meta-analysis. [2022]

9. England pubmed.ncbi.nlm.nih.gov

Educating parents about youth suicide: knowledge, response to suicidal statements, attitudes, and intention to help. [2022]

10. France pubmed.ncbi.nlm.nih.gov

[Can we consider the journalist an actor in suicide prevention?] [2022]